 Cortexyme, Inc. Nasdaq: CRTX today announced that enrollment in its GAIN Trial for Alzheimers disease AD has reached 500 patients toward the studys previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 23 trial of atuzaginstat COR388, Cortexymes lead investigational medicine, in patients with mild to moderate AD. The GAIN Trials protocol includes an interim analysis on the studys co-primary cognitive and functional endpoints after approximately 300 patients reach 24 weeks of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results of the GAIN Trials final analysis, to be performed once all study subjects complete the one-year study, are expected in Q4 2021. 